The Experts below are selected from a list of 20727 Experts worldwide ranked by ideXlab platform

Nils A. Loewen - One of the best experts on this subject based on the ideXlab platform.

  • Coarsened Exact Matching of Trabectome Surgery Combined with Baerveldt to Baerveldt: Same Session Trabectome Negates Tube Fenestration
    2018
    Co-Authors: Hamed Esfandiari, Peter Knowlton, Mehdi Yaseri, Kiana Hassanpour, Tarek A. Shazly, Nils A. Loewen
    Abstract:

    Purpose: To evaluate the efficacy and survival rates of trabectome-mediated ab interno trabeculectomy combined with non-fenestrated Baerveldt Glaucoma implants (BT) in comparison to Baerveldt Glaucoma implant alone (B).Method: A total of 175 eyes undergoing Primary Glaucoma surgery (60 eyes BT and 115 B) were enrolled in this retrospective comparative case series. Participants were identified using the procedural terminology codes. Groups were then matched using Coarsened Exact Matching (51 eyes in each group). The Primary outcome measure was surgical success, defined as 5 mmHg < IOP ≤ 21 mmHg, and IOP reduction ≥ 20% from baseline, and no reoperation for Glaucoma. Secondary outcome measures were intraocular pressure, the number of Glaucoma medications, and best corrected visual acuity (BCVA).Results: The cumulative probability of success at one year was 61% in BT, and 50% in B. IOP decreased significantly from 23.5±2.4 mmHg at baseline to 14.1±2.7 mmHg at the final follow up in BT (P= 0.001). The corresponding numbers for B were 23.2± 2.0 and 13.9± 1.6, respectively (P= 0.001). There was no significant difference in IOP at the final follow-up (P=0.56). The number of medications at baseline was 2.3±0.3 in both groups. However, BT needed significantly fewer drops at all postoperative time intervals and used 1.1±0.3 (BT) and 2.0±0.4 eye drops (B) at the final follow-up visit (P= 0.004). No dangerous hypotony or hypertension occurred in BT.Conclusion: Similar rates of success and IOP reduction were observed in BT and B. BT needed significantly fewer Glaucoma medications. Tube fenestration was not necessary in BT resulting in less postoperative hypotony and hypertension.

  • Impact of same-session trabectome surgery on Ahmed Glaucoma valve outcomes
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2018
    Co-Authors: Hamed Esfandiari, Mehdi Yaseri, Kiana Hassanpour, Tarek A. Shazly, Priyal Shah, Pooya Torkian, Nils A. Loewen
    Abstract:

    Purpose To evaluate the efficacy and survival rates of same session ab interno trabeculectomy with the trabectome and Ahmed Glaucoma valve implant (AT) in comparison to the Ahmed Glaucoma valve alone (A). Method A total of 107 eyes undergoing Primary Glaucoma surgery were enrolled in this retrospective comparative case series, including 48 eyes which underwent AT and 59 eyes which received A alone. Participants were identified using the procedural terminology codes, and their medical records were reviewed. The Primary outcome measure was success defined as IOP > 5 mmHg, ≤ 21 mmHg and ≥ 20% reduction of IOP from baseline at two consecutive visits after 3 months, and no need for Glaucoma reoperation. Secondary outcome measures were IOP, the number of Glaucoma medications, incidence of a hypertensive phase, and best corrected visual acuity (BCVA). Results The cumulative probability of success at 1 year was 70% in AT, and 65% in A ( p  = 0.85). IOP decreased significantly from 26.6 ± 10.1 mmHg at baseline to 14.7 ± 3.3 mmHg at the final follow-up in AT ( p  = 0.001). The corresponding numbers for A were 27.8 ± 10.2 and 16.7 ± 4.9, respectively ( p  = 0.001). The final IOP was significantly lower in AT ( p  = 0.022). The number of medications at baseline was comparable in both groups (2.6 ± 1.2 in AT and 2.5 ± 1.3 in A, p  = 0.851). Corresponding number at 1 year visit was 1.2 ± 2 in AT and 2.8 ± 1.8 in A ( p  = 0.001). The incidence of a hypertensive phase was 18.7% in AT and 35.5% in A ( p  = 0.05). HP resolved in only 30% of eyes. The criteria for HP resolution were fulfilled in 9 eyes (30%). There was no difference in the rate of resolution of the hypertensive phase between AT and A (33.3 and 28.5%, respectively, p  = 0.67). Conclusion Ahmed Glaucoma valve implant with same session trabectome surgery significantly decreased the rate of the hypertensive phase and postoperative IOP as well as the number of Glaucoma medications.

  • Trabectome Surgery Combined with Baerveldt Glaucoma Implantation Negates Tube Fenestration
    2017
    Co-Authors: Hamed Esfandiari, Peter Knowlton, Yaseri Mehdi, Kiana Hassanpour, Tarek A. Shazly, Nils A. Loewen
    Abstract:

    Purpose: To evaluate the efficacy and survival rates of the same session ab interno trabeculectomy with trabectome and Baerveldt Glaucoma implant (BT) compared to Baerveldt implant alone (B). Method: A total of 175 eyes undergoing Primary Glaucoma surgery were enrolled in this retrospective comparative case series, including 60 eyes which underwent BT and 115 eyes which received B alone. Participants were identified using the procedural terminology codes, and their medical records were reviewed. The Primary outcome measure was surgical success defined as 5 mmHg > IOP ≤ 21 mmHg and IOP reduction ≥ 20% from baseline, no reoperation for Glaucoma, and no loss of light perception vision. Secondary outcome measures were intraocular pressure, the number of Glaucoma medications, and best corrected visual acuity (BCVA). Results: The cumulative probability of success at 1 year was 61% in BT, and 50% in B. IOP decreased significantly from 23.6±8.9 mmHg at baseline to 13.7±3.9 mmHg at the final follow up in BT (P= 0.001). The corresponding numbers for B were 23.3±7.5 and 14.2±4.5, respectively (P= 0.001). There was no significant difference in IOP at the final follow-up (P=0.56). The number of medications at baseline was comparable in both groups (2.1±1.1 in BT versus 2.4±1 in B, p=0.07). However, BT needed statistically significant fewer drops in all postoperative time intervals and used 0.9±0.9 (BT) and 1.6±1.2 eyedrops (B) at the final follow-up visit (P= 0.004). No dangerous hypertony or hypertension occurred in BT. Conclusion: Similar rates of success and IOP reduction were observed in BT and B. Eyes who underwent trabectome surgery needed significantly fewer Glaucoma medications during 1-year follow-up period while tubes did not require fenestration resulting in fewer postoperative hypotony or hypertension.

Hamed Esfandiari - One of the best experts on this subject based on the ideXlab platform.

  • Coarsened Exact Matching of Trabectome Surgery Combined with Baerveldt to Baerveldt: Same Session Trabectome Negates Tube Fenestration
    2018
    Co-Authors: Hamed Esfandiari, Peter Knowlton, Mehdi Yaseri, Kiana Hassanpour, Tarek A. Shazly, Nils A. Loewen
    Abstract:

    Purpose: To evaluate the efficacy and survival rates of trabectome-mediated ab interno trabeculectomy combined with non-fenestrated Baerveldt Glaucoma implants (BT) in comparison to Baerveldt Glaucoma implant alone (B).Method: A total of 175 eyes undergoing Primary Glaucoma surgery (60 eyes BT and 115 B) were enrolled in this retrospective comparative case series. Participants were identified using the procedural terminology codes. Groups were then matched using Coarsened Exact Matching (51 eyes in each group). The Primary outcome measure was surgical success, defined as 5 mmHg < IOP ≤ 21 mmHg, and IOP reduction ≥ 20% from baseline, and no reoperation for Glaucoma. Secondary outcome measures were intraocular pressure, the number of Glaucoma medications, and best corrected visual acuity (BCVA).Results: The cumulative probability of success at one year was 61% in BT, and 50% in B. IOP decreased significantly from 23.5±2.4 mmHg at baseline to 14.1±2.7 mmHg at the final follow up in BT (P= 0.001). The corresponding numbers for B were 23.2± 2.0 and 13.9± 1.6, respectively (P= 0.001). There was no significant difference in IOP at the final follow-up (P=0.56). The number of medications at baseline was 2.3±0.3 in both groups. However, BT needed significantly fewer drops at all postoperative time intervals and used 1.1±0.3 (BT) and 2.0±0.4 eye drops (B) at the final follow-up visit (P= 0.004). No dangerous hypotony or hypertension occurred in BT.Conclusion: Similar rates of success and IOP reduction were observed in BT and B. BT needed significantly fewer Glaucoma medications. Tube fenestration was not necessary in BT resulting in less postoperative hypotony and hypertension.

  • Impact of same-session trabectome surgery on Ahmed Glaucoma valve outcomes
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2018
    Co-Authors: Hamed Esfandiari, Mehdi Yaseri, Kiana Hassanpour, Tarek A. Shazly, Priyal Shah, Pooya Torkian, Nils A. Loewen
    Abstract:

    Purpose To evaluate the efficacy and survival rates of same session ab interno trabeculectomy with the trabectome and Ahmed Glaucoma valve implant (AT) in comparison to the Ahmed Glaucoma valve alone (A). Method A total of 107 eyes undergoing Primary Glaucoma surgery were enrolled in this retrospective comparative case series, including 48 eyes which underwent AT and 59 eyes which received A alone. Participants were identified using the procedural terminology codes, and their medical records were reviewed. The Primary outcome measure was success defined as IOP > 5 mmHg, ≤ 21 mmHg and ≥ 20% reduction of IOP from baseline at two consecutive visits after 3 months, and no need for Glaucoma reoperation. Secondary outcome measures were IOP, the number of Glaucoma medications, incidence of a hypertensive phase, and best corrected visual acuity (BCVA). Results The cumulative probability of success at 1 year was 70% in AT, and 65% in A ( p  = 0.85). IOP decreased significantly from 26.6 ± 10.1 mmHg at baseline to 14.7 ± 3.3 mmHg at the final follow-up in AT ( p  = 0.001). The corresponding numbers for A were 27.8 ± 10.2 and 16.7 ± 4.9, respectively ( p  = 0.001). The final IOP was significantly lower in AT ( p  = 0.022). The number of medications at baseline was comparable in both groups (2.6 ± 1.2 in AT and 2.5 ± 1.3 in A, p  = 0.851). Corresponding number at 1 year visit was 1.2 ± 2 in AT and 2.8 ± 1.8 in A ( p  = 0.001). The incidence of a hypertensive phase was 18.7% in AT and 35.5% in A ( p  = 0.05). HP resolved in only 30% of eyes. The criteria for HP resolution were fulfilled in 9 eyes (30%). There was no difference in the rate of resolution of the hypertensive phase between AT and A (33.3 and 28.5%, respectively, p  = 0.67). Conclusion Ahmed Glaucoma valve implant with same session trabectome surgery significantly decreased the rate of the hypertensive phase and postoperative IOP as well as the number of Glaucoma medications.

  • Trabectome Surgery Combined with Baerveldt Glaucoma Implantation Negates Tube Fenestration
    2017
    Co-Authors: Hamed Esfandiari, Peter Knowlton, Yaseri Mehdi, Kiana Hassanpour, Tarek A. Shazly, Nils A. Loewen
    Abstract:

    Purpose: To evaluate the efficacy and survival rates of the same session ab interno trabeculectomy with trabectome and Baerveldt Glaucoma implant (BT) compared to Baerveldt implant alone (B). Method: A total of 175 eyes undergoing Primary Glaucoma surgery were enrolled in this retrospective comparative case series, including 60 eyes which underwent BT and 115 eyes which received B alone. Participants were identified using the procedural terminology codes, and their medical records were reviewed. The Primary outcome measure was surgical success defined as 5 mmHg > IOP ≤ 21 mmHg and IOP reduction ≥ 20% from baseline, no reoperation for Glaucoma, and no loss of light perception vision. Secondary outcome measures were intraocular pressure, the number of Glaucoma medications, and best corrected visual acuity (BCVA). Results: The cumulative probability of success at 1 year was 61% in BT, and 50% in B. IOP decreased significantly from 23.6±8.9 mmHg at baseline to 13.7±3.9 mmHg at the final follow up in BT (P= 0.001). The corresponding numbers for B were 23.3±7.5 and 14.2±4.5, respectively (P= 0.001). There was no significant difference in IOP at the final follow-up (P=0.56). The number of medications at baseline was comparable in both groups (2.1±1.1 in BT versus 2.4±1 in B, p=0.07). However, BT needed statistically significant fewer drops in all postoperative time intervals and used 0.9±0.9 (BT) and 1.6±1.2 eyedrops (B) at the final follow-up visit (P= 0.004). No dangerous hypertony or hypertension occurred in BT. Conclusion: Similar rates of success and IOP reduction were observed in BT and B. Eyes who underwent trabectome surgery needed significantly fewer Glaucoma medications during 1-year follow-up period while tubes did not require fenestration resulting in fewer postoperative hypotony or hypertension.

Tarek A. Shazly - One of the best experts on this subject based on the ideXlab platform.

  • Coarsened Exact Matching of Trabectome Surgery Combined with Baerveldt to Baerveldt: Same Session Trabectome Negates Tube Fenestration
    2018
    Co-Authors: Hamed Esfandiari, Peter Knowlton, Mehdi Yaseri, Kiana Hassanpour, Tarek A. Shazly, Nils A. Loewen
    Abstract:

    Purpose: To evaluate the efficacy and survival rates of trabectome-mediated ab interno trabeculectomy combined with non-fenestrated Baerveldt Glaucoma implants (BT) in comparison to Baerveldt Glaucoma implant alone (B).Method: A total of 175 eyes undergoing Primary Glaucoma surgery (60 eyes BT and 115 B) were enrolled in this retrospective comparative case series. Participants were identified using the procedural terminology codes. Groups were then matched using Coarsened Exact Matching (51 eyes in each group). The Primary outcome measure was surgical success, defined as 5 mmHg < IOP ≤ 21 mmHg, and IOP reduction ≥ 20% from baseline, and no reoperation for Glaucoma. Secondary outcome measures were intraocular pressure, the number of Glaucoma medications, and best corrected visual acuity (BCVA).Results: The cumulative probability of success at one year was 61% in BT, and 50% in B. IOP decreased significantly from 23.5±2.4 mmHg at baseline to 14.1±2.7 mmHg at the final follow up in BT (P= 0.001). The corresponding numbers for B were 23.2± 2.0 and 13.9± 1.6, respectively (P= 0.001). There was no significant difference in IOP at the final follow-up (P=0.56). The number of medications at baseline was 2.3±0.3 in both groups. However, BT needed significantly fewer drops at all postoperative time intervals and used 1.1±0.3 (BT) and 2.0±0.4 eye drops (B) at the final follow-up visit (P= 0.004). No dangerous hypotony or hypertension occurred in BT.Conclusion: Similar rates of success and IOP reduction were observed in BT and B. BT needed significantly fewer Glaucoma medications. Tube fenestration was not necessary in BT resulting in less postoperative hypotony and hypertension.

  • Impact of same-session trabectome surgery on Ahmed Glaucoma valve outcomes
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2018
    Co-Authors: Hamed Esfandiari, Mehdi Yaseri, Kiana Hassanpour, Tarek A. Shazly, Priyal Shah, Pooya Torkian, Nils A. Loewen
    Abstract:

    Purpose To evaluate the efficacy and survival rates of same session ab interno trabeculectomy with the trabectome and Ahmed Glaucoma valve implant (AT) in comparison to the Ahmed Glaucoma valve alone (A). Method A total of 107 eyes undergoing Primary Glaucoma surgery were enrolled in this retrospective comparative case series, including 48 eyes which underwent AT and 59 eyes which received A alone. Participants were identified using the procedural terminology codes, and their medical records were reviewed. The Primary outcome measure was success defined as IOP > 5 mmHg, ≤ 21 mmHg and ≥ 20% reduction of IOP from baseline at two consecutive visits after 3 months, and no need for Glaucoma reoperation. Secondary outcome measures were IOP, the number of Glaucoma medications, incidence of a hypertensive phase, and best corrected visual acuity (BCVA). Results The cumulative probability of success at 1 year was 70% in AT, and 65% in A ( p  = 0.85). IOP decreased significantly from 26.6 ± 10.1 mmHg at baseline to 14.7 ± 3.3 mmHg at the final follow-up in AT ( p  = 0.001). The corresponding numbers for A were 27.8 ± 10.2 and 16.7 ± 4.9, respectively ( p  = 0.001). The final IOP was significantly lower in AT ( p  = 0.022). The number of medications at baseline was comparable in both groups (2.6 ± 1.2 in AT and 2.5 ± 1.3 in A, p  = 0.851). Corresponding number at 1 year visit was 1.2 ± 2 in AT and 2.8 ± 1.8 in A ( p  = 0.001). The incidence of a hypertensive phase was 18.7% in AT and 35.5% in A ( p  = 0.05). HP resolved in only 30% of eyes. The criteria for HP resolution were fulfilled in 9 eyes (30%). There was no difference in the rate of resolution of the hypertensive phase between AT and A (33.3 and 28.5%, respectively, p  = 0.67). Conclusion Ahmed Glaucoma valve implant with same session trabectome surgery significantly decreased the rate of the hypertensive phase and postoperative IOP as well as the number of Glaucoma medications.

  • Trabectome Surgery Combined with Baerveldt Glaucoma Implantation Negates Tube Fenestration
    2017
    Co-Authors: Hamed Esfandiari, Peter Knowlton, Yaseri Mehdi, Kiana Hassanpour, Tarek A. Shazly, Nils A. Loewen
    Abstract:

    Purpose: To evaluate the efficacy and survival rates of the same session ab interno trabeculectomy with trabectome and Baerveldt Glaucoma implant (BT) compared to Baerveldt implant alone (B). Method: A total of 175 eyes undergoing Primary Glaucoma surgery were enrolled in this retrospective comparative case series, including 60 eyes which underwent BT and 115 eyes which received B alone. Participants were identified using the procedural terminology codes, and their medical records were reviewed. The Primary outcome measure was surgical success defined as 5 mmHg > IOP ≤ 21 mmHg and IOP reduction ≥ 20% from baseline, no reoperation for Glaucoma, and no loss of light perception vision. Secondary outcome measures were intraocular pressure, the number of Glaucoma medications, and best corrected visual acuity (BCVA). Results: The cumulative probability of success at 1 year was 61% in BT, and 50% in B. IOP decreased significantly from 23.6±8.9 mmHg at baseline to 13.7±3.9 mmHg at the final follow up in BT (P= 0.001). The corresponding numbers for B were 23.3±7.5 and 14.2±4.5, respectively (P= 0.001). There was no significant difference in IOP at the final follow-up (P=0.56). The number of medications at baseline was comparable in both groups (2.1±1.1 in BT versus 2.4±1 in B, p=0.07). However, BT needed statistically significant fewer drops in all postoperative time intervals and used 0.9±0.9 (BT) and 1.6±1.2 eyedrops (B) at the final follow-up visit (P= 0.004). No dangerous hypertony or hypertension occurred in BT. Conclusion: Similar rates of success and IOP reduction were observed in BT and B. Eyes who underwent trabectome surgery needed significantly fewer Glaucoma medications during 1-year follow-up period while tubes did not require fenestration resulting in fewer postoperative hypotony or hypertension.

Kiana Hassanpour - One of the best experts on this subject based on the ideXlab platform.

  • Coarsened Exact Matching of Trabectome Surgery Combined with Baerveldt to Baerveldt: Same Session Trabectome Negates Tube Fenestration
    2018
    Co-Authors: Hamed Esfandiari, Peter Knowlton, Mehdi Yaseri, Kiana Hassanpour, Tarek A. Shazly, Nils A. Loewen
    Abstract:

    Purpose: To evaluate the efficacy and survival rates of trabectome-mediated ab interno trabeculectomy combined with non-fenestrated Baerveldt Glaucoma implants (BT) in comparison to Baerveldt Glaucoma implant alone (B).Method: A total of 175 eyes undergoing Primary Glaucoma surgery (60 eyes BT and 115 B) were enrolled in this retrospective comparative case series. Participants were identified using the procedural terminology codes. Groups were then matched using Coarsened Exact Matching (51 eyes in each group). The Primary outcome measure was surgical success, defined as 5 mmHg < IOP ≤ 21 mmHg, and IOP reduction ≥ 20% from baseline, and no reoperation for Glaucoma. Secondary outcome measures were intraocular pressure, the number of Glaucoma medications, and best corrected visual acuity (BCVA).Results: The cumulative probability of success at one year was 61% in BT, and 50% in B. IOP decreased significantly from 23.5±2.4 mmHg at baseline to 14.1±2.7 mmHg at the final follow up in BT (P= 0.001). The corresponding numbers for B were 23.2± 2.0 and 13.9± 1.6, respectively (P= 0.001). There was no significant difference in IOP at the final follow-up (P=0.56). The number of medications at baseline was 2.3±0.3 in both groups. However, BT needed significantly fewer drops at all postoperative time intervals and used 1.1±0.3 (BT) and 2.0±0.4 eye drops (B) at the final follow-up visit (P= 0.004). No dangerous hypotony or hypertension occurred in BT.Conclusion: Similar rates of success and IOP reduction were observed in BT and B. BT needed significantly fewer Glaucoma medications. Tube fenestration was not necessary in BT resulting in less postoperative hypotony and hypertension.

  • Impact of same-session trabectome surgery on Ahmed Glaucoma valve outcomes
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2018
    Co-Authors: Hamed Esfandiari, Mehdi Yaseri, Kiana Hassanpour, Tarek A. Shazly, Priyal Shah, Pooya Torkian, Nils A. Loewen
    Abstract:

    Purpose To evaluate the efficacy and survival rates of same session ab interno trabeculectomy with the trabectome and Ahmed Glaucoma valve implant (AT) in comparison to the Ahmed Glaucoma valve alone (A). Method A total of 107 eyes undergoing Primary Glaucoma surgery were enrolled in this retrospective comparative case series, including 48 eyes which underwent AT and 59 eyes which received A alone. Participants were identified using the procedural terminology codes, and their medical records were reviewed. The Primary outcome measure was success defined as IOP > 5 mmHg, ≤ 21 mmHg and ≥ 20% reduction of IOP from baseline at two consecutive visits after 3 months, and no need for Glaucoma reoperation. Secondary outcome measures were IOP, the number of Glaucoma medications, incidence of a hypertensive phase, and best corrected visual acuity (BCVA). Results The cumulative probability of success at 1 year was 70% in AT, and 65% in A ( p  = 0.85). IOP decreased significantly from 26.6 ± 10.1 mmHg at baseline to 14.7 ± 3.3 mmHg at the final follow-up in AT ( p  = 0.001). The corresponding numbers for A were 27.8 ± 10.2 and 16.7 ± 4.9, respectively ( p  = 0.001). The final IOP was significantly lower in AT ( p  = 0.022). The number of medications at baseline was comparable in both groups (2.6 ± 1.2 in AT and 2.5 ± 1.3 in A, p  = 0.851). Corresponding number at 1 year visit was 1.2 ± 2 in AT and 2.8 ± 1.8 in A ( p  = 0.001). The incidence of a hypertensive phase was 18.7% in AT and 35.5% in A ( p  = 0.05). HP resolved in only 30% of eyes. The criteria for HP resolution were fulfilled in 9 eyes (30%). There was no difference in the rate of resolution of the hypertensive phase between AT and A (33.3 and 28.5%, respectively, p  = 0.67). Conclusion Ahmed Glaucoma valve implant with same session trabectome surgery significantly decreased the rate of the hypertensive phase and postoperative IOP as well as the number of Glaucoma medications.

  • Trabectome Surgery Combined with Baerveldt Glaucoma Implantation Negates Tube Fenestration
    2017
    Co-Authors: Hamed Esfandiari, Peter Knowlton, Yaseri Mehdi, Kiana Hassanpour, Tarek A. Shazly, Nils A. Loewen
    Abstract:

    Purpose: To evaluate the efficacy and survival rates of the same session ab interno trabeculectomy with trabectome and Baerveldt Glaucoma implant (BT) compared to Baerveldt implant alone (B). Method: A total of 175 eyes undergoing Primary Glaucoma surgery were enrolled in this retrospective comparative case series, including 60 eyes which underwent BT and 115 eyes which received B alone. Participants were identified using the procedural terminology codes, and their medical records were reviewed. The Primary outcome measure was surgical success defined as 5 mmHg > IOP ≤ 21 mmHg and IOP reduction ≥ 20% from baseline, no reoperation for Glaucoma, and no loss of light perception vision. Secondary outcome measures were intraocular pressure, the number of Glaucoma medications, and best corrected visual acuity (BCVA). Results: The cumulative probability of success at 1 year was 61% in BT, and 50% in B. IOP decreased significantly from 23.6±8.9 mmHg at baseline to 13.7±3.9 mmHg at the final follow up in BT (P= 0.001). The corresponding numbers for B were 23.3±7.5 and 14.2±4.5, respectively (P= 0.001). There was no significant difference in IOP at the final follow-up (P=0.56). The number of medications at baseline was comparable in both groups (2.1±1.1 in BT versus 2.4±1 in B, p=0.07). However, BT needed statistically significant fewer drops in all postoperative time intervals and used 0.9±0.9 (BT) and 1.6±1.2 eyedrops (B) at the final follow-up visit (P= 0.004). No dangerous hypertony or hypertension occurred in BT. Conclusion: Similar rates of success and IOP reduction were observed in BT and B. Eyes who underwent trabectome surgery needed significantly fewer Glaucoma medications during 1-year follow-up period while tubes did not require fenestration resulting in fewer postoperative hypotony or hypertension.

Vera Haynatzka - One of the best experts on this subject based on the ideXlab platform.

  • long term follow up of Primary Glaucoma surgery with ahmed Glaucoma valve implant versus trabeculectomy
    American Journal of Ophthalmology, 2003
    Co-Authors: Roy M Wilson, Upali Mendis, Amit Paliwal, Vera Haynatzka
    Abstract:

    Abstract Purpose To compare the long-term results of trabeculectomy and Ahmed Glaucoma valve implant in the initial surgical management of Primary open- and closed-angle Glaucoma. Design Randomized controlled clinical trial. Methods One eye each of consecutive patients with Primary Glaucoma and without prior intraocular surgery was randomized to receive either trabeculectomy or the Ahmed implant. Setting Large university-affiliated eye hospital in Columbo, Sri Lanka. Results Of 123 patients, 64 were randomized to trabeculectomy and 59 to the Ahmed implant. With a mean follow-up of 31 months, the trabeculectomy group had statistically lower intraocular pressures (IOP) during the first postoperative year. After the first year, the IOPs were comparable. No statistically significant differences between groups were noted for postoperative visual acuity, visual field, anterior chamber depth, and short-term or long-term complications. Adjunctive medication requirement was comparable for both groups. The cumulative probabilities of success (IOP P = .86). Conclusion Lower IOPs were noted for the trabeculectomy group during the first year. With longer follow-up, the IOPs and the cumulative probabilities of success were comparable between the two groups.